Healthcare tech company Privia Health Group (NASDAQ:PRVA) will be announcing earnings results tomorrow before market open. Here’s what to expect.

Privia Health beat analysts’ revenue expectations by 5.5% last quarter, reporting revenues of $437.9 million, up 4.9% year on year. It was a satisfactory quarter for the company, with an impressive beat of analysts’ sales volume estimates but full-year revenue guidance missing analysts’ expectations.

Is Privia Health a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Privia Health’s revenue to decline 5.2% year on year to $417.8 million, a reversal from the 21% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.20 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Privia Health has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Privia Health’s peers in the healthcare technology for providers segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Premier’s revenues decreased 14.2% year on year, meeting analysts’ expectations, and Omnicell reported revenues up 18.6%, topping estimates by 2.2%. Premier traded down 14.3% following the results while Omnicell was also down 9.5%.

Read our full analysis of Premier’s results here and Omnicell’s results here.

Valuation multiples for many growth stocks have not yet reverted to their early 2021 highs, but the market has been optimistic as of late due to a soft landing. This is an economic situation where rate hikes successfully quelled inflation but did not send the economy into a recession. Furthermore, recent rate cuts and Donald Trump's triumph in the 2024 Presidential election have been tailwinds for the market, and while some of the healthcare technology for providers stocks have shown solid performance, the group has generally underperformed, with share prices down 4.5% on average over the last month. Privia Health is up 9% during the same time and is heading into earnings with an average analyst price target of $26 (compared to the current share price of $24.78).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.